Sun Pharmaceutical Industries Ltd Q4 FY26 Results Analysis: Revenue Grows 11.2%, Margin Compresses in Q4

Sun Pharmaceutical Industries Ltd's Q4 FY26 numbers came in strong, with revenue of Rs. 14,611.79 Cr (+12.70% YoY) and PAT growth of +26.20% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Sun Pharma reported a solid FY26 with 11.2% revenue growth and 130 bps margin expansion despite Q4 margin compression. India market share gains and the US Innovative Medicines crossing $1bn are strategic positives, while US generics pricing pressure and pending FDA facility resolutions remain concerns. The pending Organon acquisition and specialty pipeline catalysts (ILUMYA, UNLOXCYT) provide medium-term alpha visibility.

Key Investment Insights

Key Positives

• FY26 consolidated revenue grew 11.2% YoY, exceeding management's mid-to-high single-digit guidance.
• FY26 EBITDA margin expanded 130 bps to 30.3% from 29.0% in FY25.
• India market share rose 0.3 ppts to 8.4% — highest gain since the Ranbaxy acquisition.
• US Innovative Medicines crossed $1 billion in FY26 revenue, a strategic milestone.
• Emerging Markets revenue grew 17.4% YoY in USD terms in Q4, the strongest geography.
• API segment grew 26.4% YoY in Q4.
• FY26 normalized CFO of Rs. 124,191.8 Mn exceeded PAT (1.08x), indicating adequate earnings quality.

Risk Factors

• Q4 EBITDA margin compressed 160 bps YoY to 27.1%, with total expenses growing 15.7% vs revenue growth of 12.7%.
• US Formulations revenue declined 1.1% YoY in USD terms, driven by generics pricing pressure and lenalidomide competition.
• Finance costs rose 46.5% YoY in FY26 to Rs. 3,389.1 Mn, outpacing revenue growth.
• Three manufacturing facilities (Halol, Mohali, Dadra) remain under FDA warning letters with no resolution timeline.
• Normalized PAT growth slowed to ~4% in FY26 after adjusting for one-time exceptional items.
• Standalone PAT declined 37.9% YoY in FY26, reflecting reduced domestic intercompany sales.